{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T19:58:32Z","timestamp":1788897512033,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TL1 TR001871"],"award-info":[{"award-number":["TL1 TR001871"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Skeletal Radiol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To investigate the associations of cumulative voriconazole dose, treatment duration, and alkaline phosphatase with voriconazole-induced periostitis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>One hundred and thirty-one patients with voriconazole use were identified using a clinical informatics tool. Health record data including age, sex, immune status, alkaline phosphatase, voriconazole levels, voriconazole dose, frequency, and treatment duration were collected. Imaging studies during the duration of treatment were reviewed by two radiology trainees and imaging features of voriconazole-induced periostitis were confirmed by a board-certified musculoskeletal radiologist. The length, location in the body, location in the bone, type, and morphology of periostitis lesions were recorded. Incident voriconazole-induced periostitis was defined as new periostitis on imaging after 28\u00a0days or more of voriconazole treatment in the absence of an alternative diagnosis. Univariate Firth\u2019s logistic regression models were performed using cumulative voriconazole dose, treatment duration, and average ALP as predictors and incident VIP as the outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were nine patients with voriconazole-induced periostitis and 122 patients without voriconazole-induced periostitis. The most common lesion location in the body was the ribs (37%) and morphology was solid (44%). A 31.5-g increase in cumulative voriconazole dose was associated with 8% higher odds of incident periostitis. Increased treatment duration (63\u00a0days) and higher average alkaline phosphatase (50\u00a0IU\/L) were associated with 7% higher odds of periostitis and 34% higher odds of periostitis, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Increased cumulative voriconazole dose, treatment duration, and average alkaline phosphatase were associated with higher odds of voriconazole-induced periostitis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00256-024-04707-2","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T22:01:32Z","timestamp":1715983292000},"page":"41-47","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Associations of cumulative voriconazole dose, treatment duration, and alkaline phosphatase with voriconazole-induced periostitis"],"prefix":"10.1007","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5896-9127","authenticated-orcid":false,"given":"Walid","family":"Ashmeik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Schir\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabby B.","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"4707_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/jof3040057","volume":"3","author":"F Bongomin","year":"2017","unstructured":"Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases\u2014estimate precision. J Fungi. 2017;3:57.","journal-title":"J Fungi"},{"key":"4707_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1179\/1973947812Y.0000000051","volume":"24","author":"M Mikulska","year":"2012","unstructured":"Mikulska M, Novelli A, Aversa F, Cesaro S, de Rosa FG, Girmenia C, et al. Voriconazole in clinical practice. J Chemother. 2012;24:311\u201327.","journal-title":"J Chemother"},{"key":"4707_CR3","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1111\/j.1600-6143.2009.02837.x","volume":"9","author":"TF Wang","year":"2009","unstructured":"Wang TF, Wang T, Altman R, Eshaghian P, Lynch JP, Ross DJ, et al. Periostitis secondary to prolonged voriconazole therapy in lung transplant recipients. Am J Transplant. 2009;9:2845\u201350.","journal-title":"Am J Transplant"},{"key":"4707_CR4","first-page":"10","volume":"7","author":"MD Bucknor","year":"2013","unstructured":"Bucknor MD, Gross AJ, Link TM. Voriconazole-induced periostitis in two post-transplant patients. J Radiol Case Rep. 2013;7:10\u20137.","journal-title":"J Radiol Case Rep"},{"key":"4707_CR5","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1148\/radiol.14122800","volume":"274","author":"TD Tailor","year":"2015","unstructured":"Tailor TD, Richardson ML. Case 215: Voriconazole-induced periostitis. Radiology. 2015;274:930\u20135.","journal-title":"Radiology"},{"key":"4707_CR6","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/cid\/ciq188","volume":"52","author":"RA Wermers","year":"2011","unstructured":"Wermers RA, Cooper K, Razonable RR, Deziel PJ, Whitford GM, Kremers WK, et al. Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin Infect Dis. 2011;52:604\u201311.","journal-title":"Clin Infect Dis"},{"key":"4707_CR7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.bbmt.2015.10.021","volume":"22","author":"MR Barajas","year":"2016","unstructured":"Barajas MR, McCullough KB, Merten JA, Dierkhising RA, Bartoo GT, Hashmi SK, et al. Correlation of pain and fluoride concentration in allogeneic hematopoietic stem cell transplant recipients on voriconazole. Biol Blood Marrow Transplant. 2016;22:579\u201383.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4707_CR8","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1093\/cid\/ciu513","volume":"59","author":"WJ Moon","year":"2014","unstructured":"Moon WJ, Scheller EL, Suneja A, Livermore JA, Malani AN, Moudgal V, et al. Plasma fluoride level as a predictor of voriconazole-induced periostitis in patients with skeletal pain. Clin Infect Dis. 2014;59:1237\u201345.","journal-title":"Clin Infect Dis"},{"key":"4707_CR9","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1182\/blood-2012-01-403030","volume":"120","author":"B Gerber","year":"2012","unstructured":"Gerber B, Guggenberger R, Fasler D, Nair G, Manz MG, Stussi G, et al. Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole. Blood. 2012;120:2390\u20134.","journal-title":"Blood"},{"key":"4707_CR10","first-page":"8","volume":"4","author":"M Sircar","year":"2016","unstructured":"Sircar M, Kotton C, Wojciechowski D, Safa K, Gilligan H, Heher E, et al. Voriconazole-induced periostitis & enthesopathy in solid organ transplant patients: case reports. J Biosci Med. 2016;4:8\u201317.","journal-title":"J Biosci Med"},{"key":"4707_CR11","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/art.42085","volume":"74","author":"L Valor-M\u00e9ndez","year":"2022","unstructured":"Valor-M\u00e9ndez L, Wacker J, Schett G, Manger B, F\u00fcrst J, Strau\u00df R, et al. Clinical images: voriconazole-induced synovitis, enthesitis, and periostitis. Arthritis Rheumatol. 2022;74:1183\u20131183.","journal-title":"Arthritis Rheumatol"},{"key":"4707_CR12","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00256-014-1865-y","volume":"43","author":"M Raghavan","year":"2014","unstructured":"Raghavan M, Hayes A. Voriconazole-associated soft tissue ossification: an undescribed cause of glenohumeral joint capsulitis. Skeletal Radiol. 2014;43:1301\u201313050.","journal-title":"Skeletal Radiol"},{"key":"4707_CR13","doi-asserted-by":"publisher","first-page":"7205","DOI":"10.1128\/AAC.00872-15","volume":"59","author":"KC Allen","year":"2015","unstructured":"Allen KC, Sanchez CJ, Niece KL, Wenke JC, Akers KS. Voriconazole enhances the osteogenic activity of human osteoblasts in vitro through a fluoride-independent mechanism. Antimicrob Agents Chemother. 2015;59:7205\u201313.","journal-title":"Antimicrob Agents Chemother"},{"key":"4707_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1148\/rg.220120","volume":"43","author":"H Allen","year":"2023","unstructured":"Allen H, Barnthouse NC, Chan BY. Periosteal pathologic conditions: imaging findings and pathophysiology. Radiographics. 2023;43:1\u201317.","journal-title":"Radiographics"},{"key":"4707_CR15","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:e1-60.","journal-title":"Clin Infect Dis"},{"key":"4707_CR16","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10067-016-3341-7","volume":"36","author":"MH Adwan","year":"2017","unstructured":"Adwan MH. Voriconazole-induced periostitis: a new rheumatic disorder. Clin Rheumatol. 2017;36:609\u201315.","journal-title":"Clin Rheumatol"},{"key":"4707_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/tid.12941","volume":"20","author":"K Poinen","year":"2018","unstructured":"Poinen K, Leung M, Wright AJ, Landsberg D. A vexing case of bone pain in a renal transplant recipient: voriconazole-induced periostitis. Transpl Infect Dis. 2018;20:1\u20136.","journal-title":"Transpl Infect Dis"},{"key":"4707_CR18","doi-asserted-by":"crossref","unstructured":"Tan I, Lomasney L, Stacy GS, Lazarus M, Mar WA. Spectrum of voriconazole-induced with review of the differential diagnosis. AJR Am J Roentgenol. 2019;212:157\u201365.","DOI":"10.2214\/AJR.18.19991"},{"key":"4707_CR19","first-page":"78","volume":"12","author":"DL Davis","year":"2015","unstructured":"Davis DL. Voriconazole-related periostitis presenting on magnetic resonance imaging. Clin Cases Miner Bone Metab. 2015;12:78\u201381.","journal-title":"Clin Cases Miner Bone Metab"},{"key":"4707_CR20","first-page":"350","volume":"27","author":"M Skaug","year":"2014","unstructured":"Skaug M, Spak C, Oza U. Painful periostitis in the setting of chronic voriconazole therapy. Proc (Bayl Univ Med Cent). 2014;27:350\u20132.","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"4707_CR21","doi-asserted-by":"publisher","first-page":"e10557","DOI":"10.1002\/jbm4.10557","volume":"6","author":"MJ Bennett","year":"2021","unstructured":"Bennett MJ, Balcerek MI, Lewis EAD, Zhang RLL, Bachmeier C, Tey S, et al. Voriconazole-associated periostitis: new insights into pathophysiology and management. JBMR Plus. 2021;6:e10557.","journal-title":"JBMR Plus"},{"key":"4707_CR22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00259-011-1922-x","volume":"39","author":"C Rossier","year":"2012","unstructured":"Rossier C, Dunet V, Tissot F, Aubry-Rozier B, Marchetti O, Boubaker A. Voriconazole-induced periostitis. Eur J Nucl Med Mol Imaging. 2012;39:375\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4707_CR23","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/pbc.25283","volume":"62","author":"K Tarlock","year":"2015","unstructured":"Tarlock K, Johnson D, Cornell C, Parnell S, Meshinchi S, Scott KB, et al. Elevated fluoride levels and periostitis in pediatric hematopoietic stem cell transplant recipients receiving long-term voriconazole. Pediatr Blood Cancer. 2015;62:918\u201320.","journal-title":"Pediatr Blood Cancer"},{"key":"4707_CR24","unstructured":"Institute of Medicine Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington DC: National Academy Press; 1997. pp. 288\u2013313."},{"key":"4707_CR25","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00204-020-02687-5","volume":"94","author":"NR Johnston","year":"2020","unstructured":"Johnston NR, Strobel SA. Principles of fluoride toxicity and the cellular response: a review. Arch Toxicol. 2020;94:1051\u201369.","journal-title":"Arch Toxicol"},{"key":"4707_CR26","doi-asserted-by":"publisher","first-page":"356","DOI":"10.5500\/wjt.v11.i9.356","volume":"11","author":"AJ Guarascio","year":"2021","unstructured":"Guarascio AJ, Bhanot N, Min Z. Voriconazole-associated periostitis: pathophysiology, risk factors, clinical manifestations, diagnosis, and management. World J Transplant. 2021;11:356\u201371.","journal-title":"World J Transplant"},{"key":"4707_CR27","doi-asserted-by":"publisher","first-page":"e5701","DOI":"10.1002\/pds.5701","volume":"33","author":"T-L Kelly","year":"2024","unstructured":"Kelly T-L, Salter A, Pratt NL. The weighted cumulative exposure method and its application to pharmacoepidemiology: a narrative review. Pharmacoepidemiol Drug Saf. 2024;33:e5701.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Skeletal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00256-024-04707-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00256-024-04707-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00256-024-04707-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T18:14:18Z","timestamp":1733940858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00256-024-04707-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["4707"],"URL":"https:\/\/doi.org\/10.1007\/s00256-024-04707-2","relation":{},"ISSN":["0364-2348","1432-2161"],"issn-type":[{"value":"0364-2348","type":"print"},{"value":"1432-2161","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]},"assertion":[{"value":"2 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was compliant with the Health Insurance Portability and Accountability Act and was approved by the institutional review board of the local university (IRB 18\u201326837). All procedures performed in this study were in accordance with the ethical standards of the local institutional review board and with the 1964 Helsinki Declaration and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}